BANGKOK
Bone marrow transplantation used to require a donor who is the recipient’s sibling, parent or child with 50% HLA matching. At the Oncology Center of Phyathai 2 International Hospital, a new, safe, pioneering treatment is offered to sufferers of Thalassemia and a number of oncology diseases. Haploidentical transplantation is an effective treatment for those who do not have a sibling donor and this “unrelated bone marrow transplant” is already saving many lives.
An interview with Dr. Suradej’s Hongeng : An expert in the field of bone marrow transplantation. He is a specialist at Pediatric Hematology and Oncology and spent a number of years working at St. Jude Children’s Hospital in Tennessee, USA, before returning to Thailand to become a professor in Pediatrics.
“Haploidentical transplantation is a treatment option for those who do not have a sibling donor. This ‘unrelated bone marrow transplant’ is now available at Phyathai 2 International Hospital with a number of successful transplants having already been completed,” said Prof. Hongeng.
The advantages of a haploidentical transplant include:
• Shorter wait time for a stem cell transplant, which is beneficial for patients with aggressive leukemias and lymphomas
• The stem cell transplant process is done in about 2-3 weeks, as opposed to several months with other methods.
Prof. Hongeng went on to explain that by using this pioneering technology, he can also help cure a number of other oncology diseases, such as sickle cell, leukemia and brain cancer in people under the age of 21, helping these youth return to a normal life. After a consultation with Prof. Hongeng, the treatment can be performed within days, thus enabling the patient to live a good quality life again. Due to Prof. Hengong’s diligent research and work, he can now provide this life changing practice at Phyathai 2 International Hospital.
Please Visit: Phyathai 2 Oncology Center
CONTACT
Phyathai
2 International Hospital
International Correspondence Center
Ms.
Pasinee Patanasiri, +66-2617-2444 ext. 2020 or 2047